PLPhilippe Lucarelli

Philippe Lucarelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Lucarelli has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas Sauter

    Life Sciences Research Unit (LSRU), Systems Biology Group, University of Luxembourg, L-4367, Belvaux, Luxembourg

    4 shared publications
  • Thomas Sauter

    Systems Biology and Epigenetics Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg

    4 shared publications
  • Ursula Klingmüller

    Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany

    4 shared publications
  • Daniel Seehofer

    Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, 13353 Berlin, Germany; Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, 04103 Leipzig, Germany

    3 shared publications
  • Georg Damm

    Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, 13353 Berlin, Germany; Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, 04103 Leipzig, Germany

    3 shared publications
  • Marcel Schilling

    Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany

    3 shared publications

Latest Publications

  • Open Access

    Machine learning-assisted neurotoxicity prediction in human midbrain organoids

    by Anna S. Monzel, Kathrin Hemmer, Tony Kaoma, Lisa M. Smits, Silvia Bolognin, Philippe Lucarelli, Isabel Rosety, Alise Zagare, Paul Antony, Sarah L. Nickels, et al.


  • Open Access

    Computational models of melanoma

    by Marco Albrecht, Philippe Lucarelli, Dagmar Kulms, Thomas Sauter

    Genes, proteins, or cells influence each other and consequently create patterns, which can be increasingly better observed by experimental biology and medicine. Thereby, descriptive methods of statistics and bioinformatics sharpen and structure our perception. However, additionally considering the interconnectivity between biological elements promises a deeper and more coherent understanding of melanoma. For instance, integrative network-based tools and well-grounded inductive in silico research reveal disease mechanisms, stratify patients, and support treatment individualization. This review gives an overview of different modeling techniques beyond statistics, shows how different strategies align with the respective medical biology, and identifies possible areas of new computational melanoma research.


  • Open Access

    Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients

    by Sarah Louise Nickels, Jonas Walter, Silvia Bolognin, Deborah Gérard, Christian Jaeger, Xiaobing Qing, Johan Tisserand, Javier Jarazo, Kathrin Hemmer, Amy Harms, et al.


  • Top Cited Papers
    Open Access

    Clinical update on head and neck cancer: molecular biology and ongoing challenges

    by Elham Alsahafi, Katheryn Begg, Ivano Amelio, Nina Raulf, Philippe Lucarelli, Thomas Sauter, Mahvash Tavassoli

    Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies, surgery and radiotherapy represent the primary treatment options for most patients. But these treatments are associated with significant morbidity and a reduction in quality of life. Resistance to both radiotherapy and the only available targeted therapy, and subsequent relapse are common. Research has therefore focussed on identifying biomarkers to stratify patients into clinically meaningful groups and to develop more effective targeted therapies. However, as we are now discovering, the poor response to therapy and aggressive nature of HNSCCs is not only affected by the complex alterations in intracellular signalling pathways but is also heavily influenced by the behaviour of the extracellular microenvironment. The HNSCC tumour landscape is an environment permissive of these tumours’ aggressive nature, fostered by the actions of the immune system, the response to tumour hypoxia and the influence of the microbiome. Solving these challenges now rests on expanding our knowledge of these areas, in parallel with a greater understanding of the molecular biology of HNSCC subtypes. This update aims to build on our earlier 2014 review by bringing up to date our understanding of the molecular biology of HNSCCs and provide insights into areas of ongoing research and perspectives for the future.


  • Open Access

    Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment

    by Kotryna Seip, Kjetil Jørgensen, Marco Vincent Haselager, Marco Albrecht, Mads Haugland Haugen, Eivind Valen Egeland, Philippe Lucarelli, Olav Engebraaten, Thomas Sauter, Gunhild Mari Mælandsmo, et al.


  • Open Access

    Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma

    by Greta Del Mistro, Philippe Lucarelli, Ines Müller, Sébastien De Landtsheer, Anna Zinoveva, Meike Hutt, Martin Siegemund, Roland E. Kontermann, Stefan Beissert, Thomas Sauter, et al.

    Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies.


  • Open Access

    Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers

    by N. Raulf, P. Lucarelli, S. Thavaraj, S. Brown, J.M. Vicencio, T. Sauter, M. Tavassoli


  • Open Access

    Using Regularization to Infer Cell Line Specificity in Logical Network Models of Signaling Pathways

    by Sébastien De Landtsheer, Philippe Lucarelli, Thomas Sauter

    Understanding the functional properties of cells of different origins is a long-standing challenge of personalized medicine. Especially in cancer, the high heterogeneity observed in patients slows down the development of effective cures. The molecular differences between cell types or between healthy and diseased cellular states are usually determined by the wiring of regulatory networks. Understanding these molecular and cellular differences at the systems level would improve patient stratification and facilitate the design of rational intervention strategies. Models of cellular regulatory networks frequently make weak assumptions about the distribution of model parameters across cell types or patients. These assumptions are usually expressed in the form of regularization of the objective function of the optimization problem. We propose a new method of regularization for network models of signaling pathways based on the local density of the inferred parameter values within the parameter space. Our method reduces the complexity of models by creating groups of cell line-specific parameters which can then be optimized together. We demonstrate the use of our method by recovering the correct topology and inferring accurate values of the parameters of a small synthetic model. To show the value of our method in a realistic setting, we re-analyze a recently published phosphoproteomic dataset from a panel of 14 colon cancer cell lines. We conclude that our method efficiently reduces model complexity and helps recovering context-specific regulatory information.


  • Open Access

    Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene Expression

    by Philippe Lucarelli, Marcel Schilling, Clemens Kreutz, Artyom Vlasov, Martin E. Boehm, Nao Iwamoto, Bernhard Steiert, Susen Lattermann, Marvin Wäsch, Markus Stepath, et al.


  • Open Access

    Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib

    by Svantje Sobotta, Andreas Raue, Xiaoyun Huang, Joep Vanlier, Anja Jünger, Sebastian Bohl, Ute Albrecht, Maximilian J. Hahnel, Stephanie Wolf, Nikola S. Mueller, et al.

    IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential equations (ODE) and the model parameters were estimated by a maximum likelihood approach, whereas identifiability of the dynamic model parameters was ensured by the Profile Likelihood. Using model simulations coupled with experimental validation we could optimize the long-term impact of the JAK-inhibitor Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted doses and timing of treatments helps to improve the reduction of inflammatory APP gene expression in primary mouse hepatocytes close to levels observed during regenerative conditions. The concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes. Thus, combining quantitative data generation with mathematical modeling suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines.